Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer

Frontiers in Oncology

Volumn 3 FEB, Issue , 2013, Pages

  Wagner, Michael J ^a   Maki, Robert G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

IGF 1R; Insulin like growth factor pathway; Pediatric cancer; Resistance mechanisms; Sarcoma

Indexed keywords

AEW 541; ANTINEOPLASTIC AGENT; BMS 536924; CIXUTUMUMAB; DOXORUBICIN; EM 164; FIGITUMUMAB; GANITUMAB; IMATINIB; LAPATINIB; MAB 391; MAMMALIAN TARGET OF RAPAMYCIN; NVP AEW 541; PEGVISOMANT; PROTEIN KINASE B; R 1507; RAPAMYCIN; ROBATUMUMAB; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR INHIBITOR; SUNITINIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; UNCLASSIFIED DRUG; VINCRISTINE;

CHILDHOOD CANCER; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; MEDULLOBLASTOMA; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RHABDOMYOSARCOMA; SHORT SURVEY; SYNOVIAL SARCOMA;

EID: 84879591354     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00009     Document Type: Short Survey

References (71)

1. Abraham, J., Prajapati, S. I., Nishijo, K., Schaffer, B. S., Taniguchi, E., Kilcoyne, A., et al. (2011). Evasion mechanism to IGF1R inhibition in rhabdomyosarcoma. Mol. Cancer Ther. 10, 697-707.
2. Agaram, N. P., Laquaglia, M. P., Ustun, B., Guo, T., Wong, G. C., Socci, N. D., et al. (2008). Molecular characterization of pediatric gastrointestinal stromal tumors. Clin. Cancer Res. 14, 3204-3215.
3. Ayalon, D., Glaser, T., and Werner, H. (2001). Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm. IGF Res. 11, 289-297.
4. Bax, D. A., Mackay, A., Little, S. E., Carvalho, D., Viana-Pereira, M., Tamber, N., et al. (2010). A distinctspectrum of copy number aberrations in pediatric high-grade gliomas. Clin. Cancer Res. 16, 3368-3377.
5. Bielen, A., Box, G., Perryman, L., Bjerke, L., Popov, S., Jamin, Y., et al. (2012). Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. Proc. Natl. Acad. Sci. U.S.A. E1267-E1276.
6. Bielen, A., Perryman, L., Box, G. M., Valenti, M., de Haven Brandon, A., Martins, V., et al. (2011). Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRa/ß. Mol. Cancer Ther. 10, 1407-1418.
7. Cao, L., Yu, Y., Darko, I., Currier, D., Mayeenuddin, L. H., Wan, X., et al. (2008). Addiction to elevated insulin-like growth factor 1 receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 68, 8039-8048.
8. De Meyts, P., and Whittaker, J. (2002). Structural biology of insulin and IGF1 receptors: Implications for drug design. Nat. Rev. Drug Discov. 1, 769-783.
9. Del Valle, L., Enam, S., Lassak, A., Wang, J. Y., Croul, S., Khalili, K., et al. (2002). Insulin-like growth factor I receptor activity in human medulloblastomas. Clin. Cancer Res. 8, 1822-1830.
10. Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., et al. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329-1338.
11. Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480.
12. El-Badry, O. M., Romanus, J. A., Helman, L. J., Cooper, M. J., Rechler, M. M., and Israel, M. A. (1989). Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J. Clin. Invest. 84, 829-839.
13. Friedrichs, N., Küchler, J., Endl, E., Koch, A., Czerwitzki, J., Wurst, P., et al. (2008). Insulin-likegrowthfactor-1receptoracts as a growth regulator in synovial sarcoma. J. Pathol. 216, 428-439.
14. Gansler, T., Furlaneto, R., Gramling, T. S., Robinson, K. A., Blocker, N., Buse, M. G., et al. (1989). Antibody to type I insulin like growth factor receptor inhibits growth of Wilms tumor in culture and in athymic mice. Am. J. Pathol. 135, 961-966.
15. Garofalo, C., Mancarella, C., Grilli, A., Manara, M. C., Astolfi, A., Marino, M. T., et al. (2012). Identification of common and distinctive mechanisms of resistance to different anti-IGF-1R agents in Ewing's sarcoma. Mol. Endocrinol. 26, 1603-1616.
16. Geoerger, B., Brasme, J. F., Daudigeos-Dubus, E., Opolon, P., Venot, C., Debussche, L., et al. (2010). Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. Eur. J. Cancer 46, 3251-3262.
17. Ghosh, P., Dahms, N. M., and Kornfeld, S. (2003). Mannose 6-phosphate receptors: new twists in the tale. Nat. Rev. Mol. Cell Biol. 4, 202-212.
18. Grimberg, A., and Cohen, P. (2000). Role of Insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Physiol. 183, 1-9.
19. Houghton, P. J., Morton, C. L., Gorlick, R., Kolb, E. A., Keir, S. T., Reynolds, C. P., et al. (2010). Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 54, 921-926.
20. Huang, F., Greer, A., Hurlburt, W., Han, X., Hafezi, X., Wittenberg, G. M., et al. (2009). The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 69, 169-170.
21. Huang, F., Hurlburt, W., Greer, A., Reeves, K. A., Hillerman, S., Chang, H., et al. (2010). Differential mechanisms of acquired resistance to insulin-like growth factor-I receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res. 70, 7221-7231.
22. Huang, H. J., Angelo, L. S., Rodon, J., Sun, M., Kuenkele, K. P., Parsons, H. A., et al. (2011). R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS ONE 6:e26060. doi: 10.1371/journal.pone.0026060
23. Italiano, A., Chen, J., Zhang, L., Hajdu, M., Singer, S., DeMatteo, R. P., et al. (2012). Patterns of deregulation of insulin growth factor signaling pathway in paediatric and adult gastrointestinal stromal tumours. Eur. J. Cancer 48, 3215-3222.
24. Janeway, K. A., Albritton, K. H., Van Den Abbeele, A. D., D'Amato, G. Z., Pedrazzoli, P., Siena, S., et al. (2009). Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr. Blood Cancer 52, 767-771.
25. Janeway, K. A., Liegl, B., Harlow, A., Le, C., Perez-Atayde, A., Kozakewich, H., et al. (2007). Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 67, 9084-8.
26. Janeway, K. A., and Pappo, A. (2012). Treatment guidelines for gastrointestinal stromal tumors in children and young adults. J. Pediatr. Hematol. Oncol. 34(Suppl. 2), S69-S72.
27. Janeway, K. A., Zhu, M. J., Barretina, J., Perez-Atayde, A., Demetri, G. D., and Fletcher, J. A. (2010). Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int. J. Cancer 127, 2718-2722.
28. Juergens, H., Daw, N. C., Geoerger, B., Ferrari, S., Villarroel, M., Aerts, I., et al. (2011). Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 29, 4534-4540.
29. Kalapurakal, J. A., Dome, J. S., Perlman, E. J., Malogolowkin, M., Haase, G. M., Grundy, P., et al. (2004). Management of Wilms Tumor: current practice and future goals. Lancet Oncol. 5, 37-46.
30. Kappel, C. C., VelezYanguas, M. C., Hirschfeld, S., and Helman, L. J. (1994). Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 54, 2803-2807.
31. Kim, S. Y., Wan, X., and Helman, L. J. (2009). Targeting IGF-1R in the treatment of sarcomas: past, present and future. Bull. Cancer 96, E52-E60.
32. Kolb, E. A., Gorlick, R., Houghton, P. J., Morton, C. L., Lock, R., Carol, H., et al. (2008). Initial testing (stage1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 1190-1197.
33. Kolb, E. A., Gorlick, R., Lock, R., Carol, H., Morton, C. L., Keir, S. T., et al. (2011). Initial testing (Stage I) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr. Blood Cancer 56, 595-603.
34. Kolb, E. A., Gorlick, R., Maris, J. M., Keir, S. T., Morton, C. L., Wu, J., et al. (2012). Combination testing (Stage2) of the Anti-IGF-1receptorantibodyIMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 58, 729-735.
35. Kolb, E. A., Kamara, D., Zhang, W., Lin, J., Hingorani, P., Baker, L., et al. (2010). R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr. Blood Cancer 55, 67-75.
36. Lee, G. Y., and Rechler, M. M. (1996). Proteolysis of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in 150-kilodalton IGFBP complexes by a cation-dependent protease activity in adult rat serum promotes the release of bound IGF-I. Endocrinology 137, 2051-2058.
37. Maki, R. G. (2010). Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J. Clin. Oncol. 28, 4985-4995.
38. Maki, R. G. (2012). "VEGFR and IGF1R inhibitors in sarcoma therapy," in Oral presentation presented at ASCO 2012, Chicago.
39. Malempati, S., Weigel, B., Ingle, A. M., Ahern, C. H., Carroll, J. M., Roberts, C. T., et al. (2012). Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 30, 256-262.
40. Maris, J. (2010). Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202-2211.
41. Martins, A. S., Mackintosh, C., Martín, D. H., Campos, M., Hernández, T., Ordóñez, J. L., et al. (2006). Insulin like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin. Cancer Res. 12, 3532-3540.
42. Mirabello, L., Troisi, R. J., and Savage, S. A. (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115, 1531-1543.
43. Naing, A., LoRusso, P., Fu, S., Hong, D. S., Anderson, P., Benjamin, R. S., et al. (2012). Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin. Cancer Res. 18, 2625-2631.
44. Natrajan, R., Reis-Filho, J. S., Little, S. E., Messahel, B., Brundler, M. A., Dome, J. S., et al. (2006). Blastemal expression of type I inslin-like growth factor receptor in Wilms tumors is driven by increased copy number and correlates with relapse. Cancer Res. 66, 11148-11155.
45. Northcott, P. A., Jones, D. T., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y. J., et al. (2012). Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12, 818-834.
46. Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., et al. (2010). Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 11, 129-135.
47. Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K. P., Chawla, S. P., et al. (2011). R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research Through Collaboration study. J. Clin. Oncol. 29, 4541-4547.
48. Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., et al. (2010). Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28, 3061-3068.
49. Petricoin, E. F. III, Espina, V., Araujo, R. P., Midura, B., Yeung, C., Wan, X., et al. (2007). Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 67, 3431-3440.
50. Pollack, M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928.
51. Potratz, J. C., Saunders, D. N., Wai, D. H., Ng, T. L., McKinney, S. E., Carboni, J. M., et al. (2010). Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res. 70, 8770-8781.
52. Prakash, S., Sarran, L., Socci, N., DeMatteo, R.P., Eisenstat, J., Greco, A. M., et al. (2005). Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J. Pediatr. Hematol. Oncol. 27, 179-187.
53. Prieur, A., Tirode, F., Cohen, P., and Delattre, O. (2004). EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 24, 7274-7283.
54. Quek, R., Wang, Q., Morgan, J. A., Shapiro, G. I., Butrynski, J. B., Ramaiya, N., et al. (2011). Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin. Cancer Res. 17, 871-879.
55. Ricort, J. M., and Binoux, M. (2001). Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinology 142, 108-113.
56. Rikhof, B., de Jong, S., Suurmeijer, A. J., Meijer, C., and van der Graaf, W. T. (2009). The insulin-like growth factor system and sarcomas. J. Pathol. 217, 469-482.
57. Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M. Y., Yu, M., et al. (2010). Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 70, 512-519.
58. Schwartz, G. K., Tap, W. D., Qin, L. X., Livingston, M. B., Undevia, S. D., Chmielowski, B., et al. (2012). "The phase II Trial of the mTOR inhibitor temsirolimus and the IGF-1R inhibitor cixutumumab (IMC-A12) in patients with IGF-1R (+) and IGF-1R (-) bone and soft tissue sarcoma (STS)," in Annual Meeting of the American Society of Clinical Oncology, Chicago. Abstract 10003.
59. Scotlandi, K., Benini, S., Nanni, P., Lollini, P, L., Nicoletti, G., Landuzzi, L., et al. (1998). Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 58, 4127-4131.
60. Spillane, A. J., A'Hern, R., Judson, I. R., Fisher, C., and Thomas, J. M. (2000). Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J. Clin. Oncol. 18, 3794-3803.
61. Sun, Y., Gao, D., Liu, Y., Huang, J., Lessnick, S., and Tanaka, S. (2006). IGF-2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 25, 1042-1052.
62. Tap, W. D., Demetri, G., Barnette, P., Desai, J, Kavan, P., Tozer, R., et al. (2012). Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J. Clin. Oncol. 30, 1849-1856.
63. Tolcher, A. W., Sarantopoulos, J., Patnaik, A., Papadopoulos, K., Lin, C. C., Rodon, J., et al. (2009). Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27, 5800-5807.
64. van Golen, C. M., Schwab, T. S., Kim, B., Soules, M. E., Su Oh, S., Fung, K., et al. (2006). Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res. 66, 6570-6578.
65. Wan, X., Harkavy, B., Shen, N., Grohar, P., and Helman, L. J. (2007). Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26, 1932-1940.
66. Wang, Y. H., Han, X. D., Qiu, Y., Xiong, J., Yu, Y., Wang, B., et al. (2012). Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J. Surg. Oncol. 105, 235-243.
67. Weroha, S. J., and Haluska, P. (2012). The insulin-like growth factor system in cancer. Endocrinol. Metab. Clin. North Am. 41, 335-350.
68. Wojtalla, A., Salm, F., Christiansen, D. G., Cremona, T., Cwiek, P., Shalaby, T., et al. (2012). Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS ONE 7:e47109. doi: 10.1371/journal.pone.0047109
69. Xiao, S. J., Pressey, J. G., and Barr, F. G. (2002). Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol. Ther. 1, 97-104.
70. Xie, Y., Skytting, B., Nilsson, G., Brodin, B., and Larsson, O. (1999). Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res. 59, 3588-3591.
71. Yee, D., Favoni, R. E., Lebovic, G. S., Lombana, F., Powell, D. R., Reynolds, C. P., et al. (1990). Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J. Clin. Invest. 86, 1806-1814.